This event is archived. Final snapshot from when the story concluded. View on Dashboard
Events / Business / Immutep Trial Discontinuation, Class Action
Business class action

Immutep Trial Discontinuation, Class Action

Analysis based on 40 articles · First reported Apr 01, 2026 · Last updated May 10, 2026

Sentiment
-70
Attention
4
Articles
40
Market Impact
General
Live prominence charts, article sentiment distribution, and event development timeline available on the Ergen Dashboard
Market Impact

The discontinuation of Immutep's clinical trial led to a significant drop in its stock price, negatively impacting investors. This has prompted Rosen Law Firm to initiate a class action investigation, potentially leading to financial recovery for affected shareholders.

Biotechnology Legal Services
Event Summary

Immutep announced the discontinuation of its TACTI-004 Phase III study for non-small cell lung cancer on March 13, 2026, following an interim futility analysis. This news caused Immutep's American Depositary Receipt (ADR) price to fall by 82.6% to $0.48 per ADR. In response, Rosen Law Firm is investigating potential securities claims against Immutep, alleging the company may have issued misleading business information. The firm is preparing a class action lawsuit to recover investor losses, with attorneys Philip Kim and Lawrence Rosen listed as contacts for affected shareholders.

Entities Involved
priv
Rosen Law Firm
Importance 0.0 Sentiment 0.0
per
Philip Kim
Importance 0.0 Sentiment 0.0
per
Lawrence Rosen
Importance 0.0 Sentiment 0.0
stock
Immutep
Importance 0.0 Sentiment 0.0
Relationships
Rosen Law Firm related ↔ Philip Kim
Rosen Law Firm related ↔ Lawrence Rosen
Rosen Law Firm related ↔ Immutep
Philip Kim attorney ↔ Lawrence Rosen Philip Kim is an attorney at the Rosen Law Firm, working under the direction of founding partner Lawrence Rosen. Kim fre
Philip Kim related ↔ Immutep
Lawrence Rosen related ↔ Immutep
ERGEN INTELLIGENCE
Track this event live

Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.

Open Dashboard

About Ergen

Ergen is a news intelligence platform that converts raw news articles into structured data. It tracks events, entities, and the relationships between them, with sentiment and attention metrics derived from thousands of articles. Pages on this site are daily static snapshots from the platform's live database. For real-time tracking, search, and alerts, the full dashboard is at app.ergen.ai.